A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs SYN 023 (Primary) ; Rabies immune globulin; Rabies immune globulin; Rabies vaccine
- Indications Rabies
- Focus Pharmacodynamics
- Acronyms ARPEP
- Sponsors Synermore Biologics
- 22 Sep 2019 Status changed from not yet recruiting to recruiting.
- 21 May 2019 Status changed from planning to not yet recruiting.
- 08 Oct 2018 New trial record